Target intelligence / Profile preview

Tetanus toxin (TeNT) (TeNT)

Target
TeNT
Molecular classification
Bacterial toxin, Zinc metalloprotease, Neurotoxin
01

Overview

Tetanus toxin, also known as tetanospasmin, is an extremely potent neurotoxin produced by the anaerobic bacterium Clostridium tetani (StatPearls, 2023). It is the primary causative agent of tetanus, a disease characterized by severe muscle spasms and autonomic dysfunction (CDC, 2024). The toxin is a 150 kDa protein consisting of a heavy chain and a light chain linked by a disulfide bond (UniProt, 2024). The heavy chain mediates binding to polysialogangliosides on nerve terminals and facilitates retrograde axonal transport to the central nervous system (PubMed, 2021). The light chain functions as a zinc-dependent metalloprotease that cleaves synaptobrevin (VAMP), a protein essential for the release of inhibitory neurotransmitters like GABA and glycine (UniProt, 2024). This cleavage prevents the inhibition of motor neurons, leading to the characteristic spastic paralysis (StatPearls, 2023). Therapeutic strategies focus on neutralizing the toxin using antibodies induced by the tetanus toxoid vaccine or through the administration of tetanus immune globulin for passive protection (CDC, 2024).

Other names
TetanospasminTeLClostridium tetani neurotoxinTetanus neurotoxin
02

Mechanism of action

Neutralizing antibodies bind to specific epitopes on the tetanus toxin, particularly the C-fragment of the heavy chain, thereby preventing the toxin from binding to neuronal receptors and inhibiting its internalization and retrograde transport to the central nervous system (PubMed, 2021; CDC, 2024).

03

Biological functions

Proteolysis (UniProt, 2024)Inhibition of neurotransmitter release (StatPearls, 2023)Retrograde axonal transport (PubMed, 2021)Synaptic vesicle fusion inhibition (UniProt, 2024)
04

Disease associations

Tetanus (CDC, 2024)Infection (StatPearls, 2023)Muscle spasticity (PubMed, 2021)
05

Safety considerations

Hypersensitivity reactions (CDC, 2024)Arthus-type reaction (StatPearls, 2023)Brachial neuritis (CDC, 2024)Anaphylaxis (StatPearls, 2023)Injection site reactions (CDC, 2024)
06

Interacting drugs

Tetanus toxoid (CDC, 2024)

4 more in the full profile.

07

Biomarkers

Anti-tetanus IgG antibody titer (StatPearls, 2023)Serum neutralizing antibody levels (CDC, 2024)

Beyond the preview

Go deeper on Tetanus toxin (TeNT) (TeNT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tetanus toxin (TeNT) (TeNT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call